Brief Report: Major Depressive Disorder with Psychotic Features in Williams Syndrome: A Case Series / Francisca VALDES in Journal of Autism and Developmental Disorders, 48-3 (March 2018)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 48-3 (March 2018) . - p.947-952 Titre : Brief Report: Major Depressive Disorder with Psychotic Features in Williams Syndrome: A Case Series Type de document : texte imprimé Auteurs : Francisca VALDES, Auteur ; Christopher J. KEARY, Auteur ; Jennifer E. MULLETT, Auteur ; Michelle L. PALUMBO, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2018 Article en page(s) : p.947-952 Langues : Anglais (eng) Mots-clés : Co-morbidity  Major depressive disorder  Psychopharmacology  Psychosis  Williams syndrome Index. décimale : PER Périodiques Résumé : Descriptions of individuals with Williams syndrome (WS) and co-morbid major depressive disorder (MDD) with psychotic features have not appeared in the literature. In addition to reviewing previous reports of psychotic symptoms in persons with WS, this paper introduces clinical histories and therapeutic management strategies for three previously unreported adults with WS diagnosed with co-morbid MDD with psychotic features. Co-morbid medical disorders common in WS are highlighted with regard to safe and appropriate pharmacological treatment. The importance of assessment for co-morbid MDD with psychotic features in individuals with WS is emphasized. En ligne : https://doi.org/10.1007/s10803-017-3384-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=339 [article] Brief Report: Major Depressive Disorder with Psychotic Features in Williams Syndrome: A Case Series [texte imprimé] / Francisca VALDES, Auteur ; Christopher J. KEARY, Auteur ; Jennifer E. MULLETT, Auteur ; Michelle L. PALUMBO, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2018 . - p.947-952. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 48-3 (March 2018) . - p.947-952 Mots-clés : Co-morbidity  Major depressive disorder  Psychopharmacology  Psychosis  Williams syndrome Index. décimale : PER Périodiques Résumé : Descriptions of individuals with Williams syndrome (WS) and co-morbid major depressive disorder (MDD) with psychotic features have not appeared in the literature. In addition to reviewing previous reports of psychotic symptoms in persons with WS, this paper introduces clinical histories and therapeutic management strategies for three previously unreported adults with WS diagnosed with co-morbid MDD with psychotic features. Co-morbid medical disorders common in WS are highlighted with regard to safe and appropriate pharmacological treatment. The importance of assessment for co-morbid MDD with psychotic features in individuals with WS is emphasized. En ligne : https://doi.org/10.1007/s10803-017-3384-x Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=339

Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder / Majd AL-SOLEITI in Journal of Autism and Developmental Disorders, 52-9 (September 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-9 (September 2022) . - p.4164-4171 Titre : Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Majd AL-SOLEITI, Auteur ; Kayla BALAJ, Auteur ; Robyn P. THOM, Auteur ; Christopher J. MCDOUGLE, Auteur ; Christopher J. KEARY, Auteur Article en page(s) : p.4164-4171 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis/etiology  Cannabis  Humans  Male  Mania  Psychotic Disorders/etiology  Retrospective Studies  Young Adult  Autism  Autism spectrum disorder  Cannabidiol  Clinical trials  Delta-9-tetrahydrocannabinol Index. décimale : PER Périodiques Résumé : There is increasing interest in investigating cannabis for behavioral symptoms in individuals with autism spectrum disorder (ASD). The potential role of dysregulated cannabinoid signaling contributing to the pathophysiology of ASD is an area of active investigation. Results from retrospective and uncontrolled trials of cannabis in subjects with ASD have been published, reporting both potential benefits and adverse effects. Here, we describe the clinical course of three young adult males with ASD who developed mania or psychosis after the consistent use of cannabidiol and delta-9-tetrahydrocannabinol. Caution should be utilized with cannabis use in individuals with ASD until large-scale, replicated randomized controlled trials demonstrating efficacy, safety and tolerability have been published. En ligne : http://dx.doi.org/10.1007/s10803-021-05254-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486 [article] Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder [texte imprimé] / Majd AL-SOLEITI, Auteur ; Kayla BALAJ, Auteur ; Robyn P. THOM, Auteur ; Christopher J. MCDOUGLE, Auteur ; Christopher J. KEARY, Auteur . - p.4164-4171. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-9 (September 2022) . - p.4164-4171 Mots-clés : Autism Spectrum Disorder/diagnosis/etiology  Cannabis  Humans  Male  Mania  Psychotic Disorders/etiology  Retrospective Studies  Young Adult  Autism  Autism spectrum disorder  Cannabidiol  Clinical trials  Delta-9-tetrahydrocannabinol Index. décimale : PER Périodiques Résumé : There is increasing interest in investigating cannabis for behavioral symptoms in individuals with autism spectrum disorder (ASD). The potential role of dysregulated cannabinoid signaling contributing to the pathophysiology of ASD is an area of active investigation. Results from retrospective and uncontrolled trials of cannabis in subjects with ASD have been published, reporting both potential benefits and adverse effects. Here, we describe the clinical course of three young adult males with ASD who developed mania or psychosis after the consistent use of cannabidiol and delta-9-tetrahydrocannabinol. Caution should be utilized with cannabis use in individuals with ASD until large-scale, replicated randomized controlled trials demonstrating efficacy, safety and tolerability have been published. En ligne : http://dx.doi.org/10.1007/s10803-021-05254-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486

Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series / Robyn P. THOM in Journal of Autism and Developmental Disorders, 50-2 (February 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682 Titre : Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series Type de document : texte imprimé Auteurs : Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J. MCDOUGLE, Auteur Article en page(s) : p.676-682 Langues : Anglais (eng) Mots-clés : Anxiety  Buspirone  Williams syndrome Index. décimale : PER Périodiques Résumé : Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS. En ligne : http://dx.doi.org/10.1007/s10803-019-04301-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416 [article] Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series [texte imprimé] / Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J. MCDOUGLE, Auteur . - p.676-682. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682 Mots-clés : Anxiety  Buspirone  Williams syndrome Index. décimale : PER Périodiques Résumé : Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS. En ligne : http://dx.doi.org/10.1007/s10803-019-04301-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416

Corpus Callosum Volume and Neurocognition in Autism / Christopher J. KEARY in Journal of Autism and Developmental Disorders, 39-6 (June 2009)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 39-6 (June 2009) . - p.834-841 Titre : Corpus Callosum Volume and Neurocognition in Autism Type de document : texte imprimé Auteurs : Christopher J. KEARY, Auteur ; Nancy J. MINSHEW, Auteur ; Antonio Y. HARDAN, Auteur ; Matcheri S. KESHAVAN, Auteur ; Rahul BANSAL, Auteur ; Dhruman GORADIA, Auteur ; Serguei FEDOROV, Auteur Année de publication : 2009 Article en page(s) : p.834-841 Langues : Anglais (eng) Mots-clés : Autism Corpus-callosum Volume MRI Connectivity Neuropsychological-tests Index. décimale : PER Périodiques Résumé : The corpus callosum has recently been considered as an index of interhemispheric connectivity. This study applied a novel volumetric method to examine the size of the corpus callosum in 32 individuals with autism and 34 age-, gender- and IQ-matched controls and to investigate the relationship between this structure and cognitive measures linked to interhemispheric functioning. Participants with autism displayed reductions in total corpus callosum volume and in several of its subdivisions. Relationships were also observed between volumetric alterations and performance on several cognitive tests including the Tower of Hanoi test. These findings provide further evidence for anatomical alterations in the corpus callosum in autism, but warrant additional studies examining the relationship of this structure and specific measures of interhemispheric connectivity. En ligne : http://dx.doi.org/10.1007/s10803-009-0689-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=758 [article] Corpus Callosum Volume and Neurocognition in Autism [texte imprimé] / Christopher J. KEARY, Auteur ; Nancy J. MINSHEW, Auteur ; Antonio Y. HARDAN, Auteur ; Matcheri S. KESHAVAN, Auteur ; Rahul BANSAL, Auteur ; Dhruman GORADIA, Auteur ; Serguei FEDOROV, Auteur . - 2009 . - p.834-841. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 39-6 (June 2009) . - p.834-841 Mots-clés : Autism Corpus-callosum Volume MRI Connectivity Neuropsychological-tests Index. décimale : PER Périodiques Résumé : The corpus callosum has recently been considered as an index of interhemispheric connectivity. This study applied a novel volumetric method to examine the size of the corpus callosum in 32 individuals with autism and 34 age-, gender- and IQ-matched controls and to investigate the relationship between this structure and cognitive measures linked to interhemispheric functioning. Participants with autism displayed reductions in total corpus callosum volume and in several of its subdivisions. Relationships were also observed between volumetric alterations and performance on several cognitive tests including the Tower of Hanoi test. These findings provide further evidence for anatomical alterations in the corpus callosum in autism, but warrant additional studies examining the relationship of this structure and specific measures of interhemispheric connectivity. En ligne : http://dx.doi.org/10.1007/s10803-009-0689-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=758

Development of an adapted Clinical Global Impression scale for use in Angelman syndrome / Alexander KOLEVZON in Journal of Neurodevelopmental Disorders, 13 (2021)  

Public ISBD [article]  inJournal of Neurodevelopmental Disorders > 13 (2021) Titre : Development of an adapted Clinical Global Impression scale for use in Angelman syndrome Type de document : texte imprimé Auteurs : Alexander KOLEVZON, Auteur ; Pamela VENTOLA, Auteur ; Christopher J. KEARY, Auteur ; Gali HEIMER, Auteur ; Jeffrey L. NEUL, Auteur ; Mathews ADERA, Auteur ; Judith JAEGER, Auteur Langues : Anglais (eng) Mots-clés : Angelman Syndrome  Caregivers  Humans  Reproducibility of Results  Severity of Illness Index Index. décimale : PER Périodiques Résumé : BACKGROUND: The Clinical Global Impression-Severity (CGI-S) and CGI-Improvement (CGI-I) scales are widely accepted tools that measure overall disease severity and change, synthesizing the clinician's impression of the global state of an individual. Frequently employed in clinical trials for neuropsychiatric disorders, the CGI scales are typically used in conjunction with disease-specific rating scales. When no disease-specific rating scale is available, the CGI scales can be adapted to reflect the specific symptom domains that are relevant to the disorder. Angelman syndrome (AS) is a rare, clinically heterogeneous condition for which there is no disease-specific rating scale. This paper describes efforts to develop standardized, adapted CGI scales specific to AS for use in clinical trials. METHODS: In order to develop adapted CGI scales specific to AS, we (1) reviewed literature and interviewed caregivers and clinicians to determine the most impactful symptoms, (2) engaged expert panels to define and operationalize the symptom domains identified, (3) developed detailed rating anchors for each domain and for global severity and improvement ratings, (4) reviewed the anchors with expert clinicians and established minimally clinically meaningful change for each symptom domain, and (5) generated mock patient vignettes to test the reliability of the resulting scales and to standardize rater training. This systematic approach to developing, validating, and training raters on a standardized, adapted CGI scale specifically for AS is described herein. RESULTS: The resulting CGI-S/I-AS scales capture six critical domains (behavior, gross and fine motor function, expressive and receptive communication, and sleep) defined by caregivers and expert clinicians as the most challenging for patients with AS and their families. CONCLUSIONS: Rigorous training and careful calibration for clinicians will allow the CGI-S/-I-AS scales to be reliable in the context of randomized controlled trials. The CGI-S/-I-AS scales are being utilized in a Phase 3 trial of gaboxadol for the treatment of AS. En ligne : https://dx.doi.org/10.1186/s11689-020-09349-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Development of an adapted Clinical Global Impression scale for use in Angelman syndrome [texte imprimé] / Alexander KOLEVZON, Auteur ; Pamela VENTOLA, Auteur ; Christopher J. KEARY, Auteur ; Gali HEIMER, Auteur ; Jeffrey L. NEUL, Auteur ; Mathews ADERA, Auteur ; Judith JAEGER, Auteur. Langues : Anglais (eng) in Journal of Neurodevelopmental Disorders > 13 (2021) Mots-clés : Angelman Syndrome  Caregivers  Humans  Reproducibility of Results  Severity of Illness Index Index. décimale : PER Périodiques Résumé : BACKGROUND: The Clinical Global Impression-Severity (CGI-S) and CGI-Improvement (CGI-I) scales are widely accepted tools that measure overall disease severity and change, synthesizing the clinician's impression of the global state of an individual. Frequently employed in clinical trials for neuropsychiatric disorders, the CGI scales are typically used in conjunction with disease-specific rating scales. When no disease-specific rating scale is available, the CGI scales can be adapted to reflect the specific symptom domains that are relevant to the disorder. Angelman syndrome (AS) is a rare, clinically heterogeneous condition for which there is no disease-specific rating scale. This paper describes efforts to develop standardized, adapted CGI scales specific to AS for use in clinical trials. METHODS: In order to develop adapted CGI scales specific to AS, we (1) reviewed literature and interviewed caregivers and clinicians to determine the most impactful symptoms, (2) engaged expert panels to define and operationalize the symptom domains identified, (3) developed detailed rating anchors for each domain and for global severity and improvement ratings, (4) reviewed the anchors with expert clinicians and established minimally clinically meaningful change for each symptom domain, and (5) generated mock patient vignettes to test the reliability of the resulting scales and to standardize rater training. This systematic approach to developing, validating, and training raters on a standardized, adapted CGI scale specifically for AS is described herein. RESULTS: The resulting CGI-S/I-AS scales capture six critical domains (behavior, gross and fine motor function, expressive and receptive communication, and sleep) defined by caregivers and expert clinicians as the most challenging for patients with AS and their families. CONCLUSIONS: Rigorous training and careful calibration for clinicians will allow the CGI-S/-I-AS scales to be reliable in the context of randomized controlled trials. The CGI-S/-I-AS scales are being utilized in a Phase 3 trial of gaboxadol for the treatment of AS. En ligne : https://dx.doi.org/10.1186/s11689-020-09349-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

Parent Description of Anxiety in Angelman Syndrome / Christopher J. KEARY in Journal of Autism and Developmental Disorders, 52-8 (August 2022)  

Permalink

---

1 (1 - 6 / 6) Par page : 25 50 100 200